Wuhan Healthgen Biotechnology Corp Class A

As of June 30, 2026, Wuhan Healthgen Biotechnology Corp Class A carries a market capitalization of 18.23B, placing it among publicly traded companies globally. Its enterprise value stands at 17.58B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Wuhan Healthgen Biotechnology Corp Class A has 357.50M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Wuhan Healthgen Biotechnology Corp Class A maintains a current ratio of 3.00, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 12.94, indicating elevated leverage, while an interest coverage ratio of -27.45 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 34,174.16 in revenue per employee across its workforce of 253.00, a quick read on workforce productivity versus industry peers.

These figures are as of the close on October 22, 2026. The 50-day moving average sits at 37.11, while the 200-day moving average is 55.32.

These figures cover the twelve months ended June 30, 2026.

As of June 30, 2026, Wuhan Healthgen Biotechnology Corp Class A holds 1.02B in cash and equivalents against 368.05M in total debt, resulting in a net debt position of -755.19M. Total book value stands at 2.84B, with working capital of 1.25B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Wuhan Healthgen Biotechnology Corp Class A posted a gross margin of 56.39, reflecting its pricing power and cost economics. The operating margin of -369.67 and net profit margin of -308.93 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Wuhan Healthgen Biotechnology Corp Class A paid dividends of 0.01 per share. The dividend payout ratio of -7.79 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.